会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Phosphatidylinositol 4-kinase
    • 磷脂酰肌醇4激酶
    • US5001064A
    • 1991-03-19
    • US208429
    • 1988-06-20
    • Thomas F. Deuel
    • Thomas F. Deuel
    • C12N9/12
    • C12N9/12
    • A novel phosphatidylinositol 4-kinase isolated from bovine uterus having the following characteristics:(a) molecular weight of about 55 kDa as determined by sodium dodecylsulfate polyacrylamide gel electrophoresis;(b) K.sub.m of about 18 .mu.M for ATP;(c) K.sub.m of about 22 .mu.g/ml for phosphatidylinositol;(d) pH optimum of about 6.0 to 7.0;(e) activated by Mg.sup.2+ ;(f) inhibited by Ca.sup.2+ ;(g) utilizes ATP and 2'-dioxy-ATP as phosphoryl donors and specifically phosphorylates phosphatidylinositol on the 4-position; and(h) essentially free of phosphatidylinositol-4-phosphate 5-kinase activity determined by treatment with phorphoryl donors ADP, GTP, ITP or CTP.
    • 从牛子宫分离的新型磷脂酰肌醇4-激酶具有以下特征:(a)通过十二烷基硫酸钠聚丙烯酰胺凝胶电泳测定的约55kDa的分子量; (b)ATP约为18微米的Km; (c)磷脂酰肌醇的Km为约22μg/ ml; (d)最适pH约6.0-7.0; (e)被Mg2 +活化; (f)被Ca2 +抑制; (g)使用ATP和2'-二氧-ATP作为磷酰基供体,并特异性磷酸化磷脂酰肌醇4位; 和(h)基本上不含磷酰肌醇-4-磷酸5-磷酸激酶活性,其通过用佛波酯供体ADP,GTP,ITP或CTP处理而确定。
    • 3. 发明授权
    • Ubiquitin conjugating enzymes having transcriptional repressor activity
    • 具有转录阻遏物活性的泛素缀合酶
    • US5770720A
    • 1998-06-23
    • US706214
    • 1996-08-30
    • Thomas F. DeuelZhao-Yi WangThomas E. Shenk
    • Thomas F. DeuelZhao-Yi WangThomas E. Shenk
    • A61K38/00C07K14/11C07K14/82C12N9/00C12N15/12C12N15/31C12N15/52C12N15/85
    • C07K14/005C07K14/82C12N9/93A61K38/00C07K2319/00C12N2760/16022
    • A human ubiquitin conjugating enzyme, designated hUBC-9, its full amino acid sequence, and nucleic acid polymers which encode hUBC-9 are disclosed. In addition to having functional ubiquitin conjugating activity, this enzyme has transcriptional repressor activity which is independent of the conjugating activity. The conjugating activity of hUBC-9 enhances transcription through degradation of transcription suppressor proteins such as WT1, and possibly, of hUBC-9 itself. The repressor activity of hUBC-9 suppress gene transcription, probably by disrupting the transcriptional initiation complex through specific interactions with the DNA binding region of the TATA binding protein (TBP). In use, hUBC-9, yUBC-9 and other ubiquitin conjugating enzymes having repressor activity can be fused to proteins having a DNA binding domain, such as Gal4, or used in conjunction with reppressors such as Wilm's tumor suppressor gene product, WT1. Such enzymes and the nucleic acid polymers encoding them can be used for regulating transcription of a target gene in both pharmaceutical and non-pharmaceutical applications.
    • 公开了一种人泛素缀合酶,命名为hUBC-9,其全部氨基酸序列和编码hUBC-9的核酸聚合物。 除了具有功能泛素缀合活性之外,该酶具有独立于缀合活性的转录阻遏物活性。 hUBC-9的共轭活性通过转录抑制蛋白如WT1和可能的hUBC-9本身的降解来增强转录。 hUBC-9的阻遏物活性抑制基因转录,可能通过与TATA结合蛋白(TBP)的DNA结合区的特异性相互作用破坏转录起始复合物。 在使用中,具有阻遏物活性的hUBC-9,yUBC-9和其他泛素缀合酶可以与具有DNA结合结构域的蛋白质如Gal4融合,或与抑制因子如Wilm肿瘤抑制基因产物WT1结合使用。 这些酶和编码它们的核酸聚合物可用于调节药物和非药物应用中靶基因的转录。